Illumina's board approves GRAIL spin-off for Nasdaq listing in 2024, retaining 14.5% stake.

Illumina's board has approved the spin-off of cancer detection company GRAIL, currently a subsidiary, on June 24, 2024. GRAIL will apply for listing on Nasdaq under the ticker "GRAL". Illumina shareholders will retain their current shares and receive one share of GRAIL common stock for every six shares of Illumina common stock held. Illumina will retain a 14.5% minority stake in GRAIL.

June 03, 2024
4 Articles

Further Reading